Champions Oncology, Inc.
NASDAQ:CSBRBiotechnology
-$0.08 today
- Market cap
- $61.80M
- Beta
- 0.40
- P/E (TTM)
- -41.0
- EPS (TTM)
- -$0.16
Volume 0.01M
Average 0.01M
CSBR Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Champions Oncology, Inc.NASDAQ: CSBR
Cash & Equivalents · Q3 FY2026 · quarter ended Jan 2026
Cash & equivalents rises 122.6% from a year ago
Cash & equivalents stood at $7.13M at the end of Q3 FY2026, up 122.6% from a year earlier and down 16.3% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.
Context
- Cash & equivalents amounted to 25.1% of total assets at the end of Q3 FY2026, up 14.6 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +122.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 9.79M USD
- Year-over-year change
- +273.8%
- 4-year CAGR
- +20.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | 9.79M | +273.8% |
| FY2024 | 2024-04-30 | 2.62M | -74.1% |
| FY2023 | 2023-04-30 | 10.12M | +12.3% |
| FY2022 | 2022-04-30 | 9.01M | +92.2% |
| FY2021 | 2021-04-30 | 4.69M | — |
Cash & Equivalents vs competitors
How CSBR compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +122.6% is the highest of 10, against a peer median of -39.6%.
- Cash & equivalents amounts to 25.1% of total assets for CSBR, versus a peer median of 31.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $90.42M USD | +48.5% | +4.6% | 88.5% | |
IMAImageneBio Inc | Mar 2026 | $76.05M USD | +106.9% | -16.4% | 55.6% |
| Mar 2026 | $73.68M USD | -30.6% | +7.1% | 30.4% | |
| Dec 2025 | $38.35M USD | -51.0% | -21.4% | 68.4% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $34.43M USD | -65.9% | +217.7% | 31.4% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $20.96M USD | -31.1% | -36.1% | 19.8% |
| Mar 2026 | €15.01M EUR | -68.3% | -0.5% | 30.7% | |
| Mar 2026 | $13.2M USD | -82.3% | +4.3% | 4.9% | |
| Mar 2026 | $8.36M USD | -39.6% | -55.0% | 41.8% | |
| Jan 2026 | $7.13M USD | +122.6% | +2.8% | 25.1% | |
| Peer median (excluding CSBR) | — | -39.6% | -0.5% | 31.4% | |
Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Apr 2021 | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.69M | 9.01M | 10.12M | 2.62M | 9.79M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 6.99M | 9.51M | 8.01M | 9.53M | 11.23M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 1.33M | 1.5M | 1.35M |
| Total Current Assets | 12.63M | 19.66M | 19.46M | 13.64M | 22.37M |
| Property, Plant & Equipment (Net) | 14.61M | 15.36M | 14.5M | 11.97M | 9.46M |
| Goodwill | 335K | 335K | 335K | 335K | 335K |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 15K | 15K | 15K | 185K | 185K |
| Total Non-current Assets | 14.96M | 15.71M | 14.85M | 12.49M | 9.98M |
| Total Assets | 27.59M | 35.38M | 34.31M | 26.13M | 32.34M |
| Account Payables | 1.89M | 2.87M | 5.33M | 5.8M | 4.25M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 6.26M | 11.07M | 12.78M | 12.09M | 15.44M |
| Other Current Liabilities | 0 | 72K | 145K | 150K | 135K |
| Total Current Liabilities | 11.2M | 17.48M | 21.73M | 21.54M | 23.85M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 181K | 391K | 551K | 401K | 85K |
| Total Non-current Liabilities | 8.96M | 8.8M | 7.94M | 6.49M | 4.72M |
| Total Liabilities | 20.16M | 26.28M | 29.68M | 28.04M | 28.57M |
| Common Stock | 13K | 14K | 14K | 14K | 14K |
| Retained Earnings | (72.53M) | (71.98M) | (77.32M) | (84.59M) | (79.89M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 7.43M | 9.1M | 4.64M | (1.9M) | 3.77M |
| Total Debt | 9.6M | 9.47M | 8.6M | 7.43M | 6.11M |
| Net Debt | 4.91M | 459K | (1.52M) | 4.81M | (3.68M) |
Champions Oncology, Inc.
NASDAQ:CSBR
Intrinsic Alpha fair value
Locked
Current Price
$4.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.